Baker McKenzie has advised Sumitomo Rubber Industries, on the share transfer of Lonstroff. The company is a subsidiary for the manufacture and sale of rubber parts for medical applications. Sumitomo Rubber Industries concluded an agreement
Tags :Manuel Meyer
Baker McKenzie has advised the Bern-based horticultural group B+G Schweiz, which successfully completed the acquisition of 100% of the shares of Nova Concept Piscines et Jardins, based in Massongex, via Menétrey. The purchase will
Baker McKenzie advised the shareholders of SpotMe Holding (“SpotMe”), a Lausanne-based company providing end-to-end event technology solutions, in connection with the sale of a majority stake to Swiss Post. SpotMe will continue to operate globally
The German life science and medtech private equity firm SHS Capital has made a EUR 10 million investment in Simulands, a Swiss manufacturer of simulation devices for medical training of cardiovascular interventions. The investment aims to
Baker McKenzie has advised Tandem Diabetes Care, a global insulin delivery and diabetes technology company, on its purchase of AMF Medical, a privately held Swiss insulin patch pump developer. AMF Medical’s technology aligns well
Baker McKenzie Switzerland has advised Bächler + Güttinger, a renowed gardening and landscaping company in Switzerland, on its merger with three well established Swiss gardening and landscaping businesses, namely Menétrey, based in the
Edyn hospitality group has acquired Hotel Ascot in Zurich, which will reopen in summer 2023 under the name of edyn’s lifestyle brand, Locke. The purchase is edyn’s first entry into Switzerland and continues the
Baker McKenzie advised the Roth Group, a portfolio company of the Patrimonium Private Equity Fund, in taking over Lausanne-based Lambda technique d’isolation or the Lambda Group. The Roth Group is thus strengthening its presence
Deal & transactions
Healthcare specialist Apposite Capital acquires specialist CRO 1MED. The advisors
Apposite Capital, healthcare specialist private equity investor, announced its acquisition of 1MED, the Swiss based Contract Research Organization (CRO) for an undisclosed amount. Apposite Capital will work with the 1MED management team to continue to
